Key facts
- It has raised $670K; the latest was Seed Round ($670K) in Oct 2025.
- Notable investors include TOHOKU University Venture Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Asahihi Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Asahihi Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asahihi Pharmaceutical
Developer of a pharmaceutical drug development company designed for repurposing discontinued drug candidates to address unmet medical needs. The company identifies, acquires, and clinically reevaluates potential compounds with prior safety data, conducts new indication assessments, and prepares for targeted clinical trials, enabling biotechnology and healthcare sectors to accelerate drug availability while reducing early-stage development risk and cost.
- Sector
- Healthcare
- HQ
- Tsukuba, Japan
- Ownership
- Privately Held (backing)
Asahihi Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asahihi Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asahihi Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.